New drug duo aims to shrink lung tumors in first-line therapy

NCT ID NCT07353957

Recruiting now Disease control Sponsor: Merus B.V. Source: ClinicalTrials.gov ↗

First seen Jan 30, 2026 · Last updated May 15, 2026 · Updated 13 times

Summary

This study tests whether adding petosemtamab to the standard immunotherapy pembrolizumab can shrink tumors in people with advanced non-small cell lung cancer who have not had prior treatment. About 180 adults with either squamous or non-squamous lung cancer will receive the combination. The main goal is to see how many patients have their tumors shrink or disappear.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Australia Site 1
RECRUITING

Frankston, Victoria, 3199, Australia
Tennessee Site 1
RECRUITING

Nashville, Tennessee, 37209, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Tennessee Site 2
RECRUITING

Chattanooga, Tennessee, 37403, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Virginia Site 1
RECRUITING

Fairfax, Virginia, 22031, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Virginia Site 2
RECRUITING

Blacksburg, Virginia, 24060, United States

Conditions

Explore the condition pages connected to this study.

LUNG CANCER - NON SMALL CELL NON-SQUAMOUS LUNG CANCER - NON SMALL CELL SQUAMOUS